| Market Capitalization (Millions $) |
25 |
| Shares
Outstanding (Millions) |
1 |
| Employees |
10 |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-12 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Vyne Therapeutics Inc. is a biopharmaceutical company that focuses on developing and commercializing therapeutics for the treatment of various eye diseases. The company was founded in 2017 and is headquartered in Irvine, California.
Vyne Therapeutics is committed to developing innovative and effective treatments for eye diseases, using advanced technologies and scientific approaches to address unmet needs in ophthalmology. The company's primary focus is on treating dry eye disease, which affects millions of people worldwide.
The company has developed a pipeline of novel and differentiated drug candidates for the treatment of dry eye disease. These candidates are designed to address the underlying causes of the condition, such as inflammation and oxidative stress, rather than just addressing the symptoms.
One of the key products in Vyne Therapeutics' pipeline is VYN201, a first-in-class anti-inflammatory and anti-oxidant agent. The drug is designed to target multiple pathways involved in the inflammation and oxidative stress associated with dry eye disease, providing a more comprehensive treatment approach than currently available therapies.
Another product in the company's pipeline is VYN202, a small molecule that targets the TRPM8 ion channel. This channel is involved in regulating tear production, and VYN202 is designed to promote tear secretion and reduce dry eye symptoms.
In addition to its novel drug candidates, Vyne Therapeutics also has a strong focus on clinical development and regulatory affairs. The company's team of experienced researchers and clinicians are dedicated to conducting rigorous clinical trials and obtaining regulatory approvals for its products.
Overall, Vyne Therapeutics is a promising biopharmaceutical company that is focused on developing innovative and effective treatments for dry eye disease. With a strong pipeline, experienced team, and commitment to clinical development, the company is well-positioned for future success in the ophthalmology market.
Company Address: P.O. Box 125 Stewartsville 8886 NJ
Company Phone Number: 775-7936 Stock Exchange / Ticker: NASDAQ VYNE
|
%
188.66 %